// App-Quantinova.ai

: Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function

Researchers

Presenter

  • Wim A Wuyts

Principal Investigators

  • Arata Azuma

  • Jörg H W Distler

  • Klaus Sondergaard

  • Susanna Proudman

  • Vincent Cottin

  • Elvira Erhardt

  • Manuel Quaresma

  • Martina Gahlemann

  • Margarida Alves

  • Toby M Maher

Medical Centers

  • Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium,

  • Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan

  • University of Erlangen-Nuernberg, Erlangen, Germany

  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

  • Royal Adelaide Hospital and Discipline of Medicine, University of Adelaide, Adelaide, Australia

  • National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France,

  • mainanalytics GmbH, Sulzbach, Germany

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Boehringer Ingelheim (Schweiz), GmbH, Basel, Switzerland,

  • National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom

Locations

  • Belgium

  • Japan

  • Germany

  • Denmark

  • Australia

  • France

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved